ASX
NeuroScientific Biopharmaceuticals
NSB:ASX•Healthcare
Sensitive ASX Announcement
Leading CRO Appointed for Phase 2 Crohn's Trial
Published: 01/10/26, 09:38am (AEST)•3 pages